Arcturus Therapeutics Holdings Inc. (ARCT) Guidance & Earnings Results
On 2025-11-10 Arcturus Therapeutics Holdings Inc. lowered guidance: "KOSTAIVE BLA filing delayed indefinitely; additional cost reductions planned in…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARCTArcturus Therapeutics Holdings Inc.Follow ARCT — free
—
Price chart with a free account
- Market cap
- 279.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 10 Nov 25 | Lowered | KOSTAIVE BLA filing delayed indefinitely; additional cost reductions planned in Q4 |
| 11 Aug 25 | Mixed | G&A expenses expected to decrease slightly; cash runway extended into 2028. |
Arcturus Therapeutics Holdings Inc. — questions
- What guidance did Arcturus Therapeutics Holdings Inc. give?
- On 2025-11-10: "KOSTAIVE BLA filing delayed indefinitely; additional cost reductions planned in Q4"
- When does Arcturus Therapeutics Holdings Inc. report earnings?
- Arcturus Therapeutics Holdings Inc.'s next earnings report is expected on 2026-11-11.
Every figure on this page comes from Arcturus Therapeutics Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.